Review of the Use of Animal Models of Human Polycystic Kidney Disease for the Evaluation of Experimental Therapeutic Modalities

被引:8
|
作者
Nagao, Shizuko [1 ]
Yamaguchi, Tamio [1 ,2 ]
机构
[1] Fujita Hlth Univ, Adv Res Ctr Anim Models Human Dis, Toyoake 4701192, Japan
[2] Suzuka Univ Med Sci, Fac Hlth Sci, Dept Med Technol, Suzuka 5100293, Japan
关键词
cystic kidney; animal model; spontaneous; mutation; gene targeting; MOUSE MODELS; CYST GROWTH; PROGRESSION; EXPRESSION; TOLVAPTAN; RAT;
D O I
10.3390/jcm12020668
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, and nephronophthisis are hereditary disorders with the occurrence of numerous cysts in both kidneys, often causing chronic and end-stage renal failure. Animal models have played an important role in recent advances in research not only on disease onset and progressive mechanisms but also on the development of therapeutic interventions. For a long time, spontaneous animal models have been used as the primary focus for human diseases; however, after the identification of the nucleotide sequence of the responsible genes, PKD1, PKD2, PKHD1, and NPHPs, various types of genetically modified models were developed by genetic and reproductive engineering techniques and played the leading role in the research field. In this review, we present murine models of hereditary renal cystic diseases, discussing their potential benefits in the development of therapeutic strategies.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans
    Magistroni, Riccardo
    Boletta, Alessandra
    JOURNAL OF NEPHROLOGY, 2017, 30 (04) : 511 - 519
  • [22] Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans
    Riccardo Magistroni
    Alessandra Boletta
    Journal of Nephrology, 2017, 30 : 511 - 519
  • [23] Therapeutic Advances in the Treatment of Polycystic Kidney Disease
    Riella, Cristian
    Czarnecki, Peter G.
    Steinman, Theodore I.
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 297 - 302
  • [24] Animal Models for Human Polycystic Ovary Syndrome (PCOS) Focused on the Use of Indirect Hormonal Perturbations: A Review of the Literature
    Ryu, Youngjae
    Kim, Sung Woo
    Kim, Yoon Young
    Ku, Seung-Yup
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
  • [25] POLYCYSTIC OVARIAN DISEASE - ANIMAL-MODELS
    MAHAJAN, DK
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1988, 17 (04) : 705 - 732
  • [26] Determining the therapeutic potential of experimental antibacterial agents: The use of animal models
    Alder, JD
    CURRENT PHARMACEUTICAL DESIGN, 1997, 3 (02) : 143 - 158
  • [27] Elevated TGFβ-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease
    Hassane, Sabrine
    Leonhard, Wouter N.
    van der Wal, Annemieke
    Hawinkels, Lukas J. A. C.
    Lantinga-van Leeuwen, Irma S.
    ten Dijke, Peter
    Breuning, Martijn H.
    de Heer, Emile
    Peters, Dorien J. M.
    JOURNAL OF PATHOLOGY, 2010, 222 (01): : 21 - 31
  • [28] A REVIEW OF POLYCYSTIC KIDNEY-DISEASE
    LANIUS, K
    PEARSON, J
    JOURNAL OF DIAGNOSTIC MEDICAL SONOGRAPHY, 1992, 8 (05) : 232 - 237
  • [29] Experimental animal models and their use in understanding cysticercosis: A systematic review
    Sitali, Muloongo C.
    Schmidt, Veronika
    Mwenda, Racheal
    Sikasunge, Chummy S.
    Mwape, Kabemba E.
    Simuunza, Martin C.
    da Costa, Clarissa P.
    Winkler, Andrea S.
    Phiri, Isaac K.
    PLOS ONE, 2022, 17 (07):
  • [30] Use of disease models in the development and evaluation of therapeutic agents
    Reeve-Johnson, L
    VETERINARY RECORD, 1998, 142 (23) : 638 - 642